Browse Articles

Discover research articles across all indexed journals

Early findings from a national quality improvement (QI) program to address disparities in bladder cancer (BLCA) care.

Journal of Clinical Oncology Ali Raza Khaki, Fionna Sun, Patrick J. Hensley et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.697

697 Background: Rates of guideline-concordant treatment for BLCA remain <50%, driven by access and care delivery barriers. The Association of Cancer Care Centers (ACCC) designed a 6-month QI program to identify and implement site-specific strategies to support equitable care delivery at cancer programs. We aim to characterize findings from participating sites’ pre-implementation assessments as well as initial directions for QI. Methods: The ACCC QI program was conducted with cancer programs between November 2023 – November 2024, guided by an advisory committee, patient advocacy partners, and multidisciplinary faculty. Each program completed a pre-assessment to characterize organizational resources, catchment population demographics, patient volume, sentiment regarding organizational culture, practice patterns and identified barriers. Open-ended questions and those regarding sentiment used a 5-point Likert scale. During each in-person workshop, participants discussed barriers and prioritized interventions using an impact-feasibility matrix. Descriptive summary data are presented. Results: Three programs (one in California, North Carolina and Kentucky) were selected; one in an urban setting and two suburban; two NCI-designated and one Comprehensive Community Cancer program. Annual case volumes ranged from 103-1439, with 167-220 new diagnoses; >50% of cases were non-muscle invasive at each site and male-predominant (up to 30% female), with variable patient diversity (up to 50% Asian and 15% Black). Insurance coverage varied across programs: 52-80% Medicare, 17-29% Private, 0-3% uninsured. All programs agreed/strongly agreed leadership, staff and multidisciplinary team members were committed to improving equitable care, but only 1 program had processes to regularly assess disparities and 1 felt they had adequate training or culturally appropriate educational materials. Program-specific barriers to care included limitations around transportation support, limited care coordination, few community practitioners providing specialized care, and limited awareness of available resources. Based on impact and feasibility ratings, intervention targets included assessing and aligning care coordination preferences, mapping supportive care resources and addressing gaps, and tailoring educational materials to patient populations. Conclusions: Our study demonstrates a strong recognition by health systems of disparities affecting BLCA care, shows the feasibility of developing a QI program focused on addressing disparities in diverse practice settings and highlights the importance of systems-level support. Implementing mitigation strategies require program-specific understanding of barriers to provide equitable care. Health systems level strategies require a community-based approach to address barriers and deliver equitable care tailored to the needs of communities served.

A novel CD28 x Nectin-4 costimulatory bispecific antibody for advanced bladder cancer.

Journal of Clinical Oncology Thomas Manley, Starlynn Clarke, Manpreet Kaur et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.810

810 Background: Effective T-cell activation is driven by multiple signals. CD3 bispecific antibodies (bsAbs) stimulate T-cell activation through the TCR. CD3 bsAbs demonstrate durable responses in hematological malignancies, but multiple clinical trials suggest that signaling through CD3 alone is insufficient to treat solid tumors. Recent results suggest that a robust T-cell response in solid tumors can be achieved by tumor-targeted costimulatory bsAbs that promote sustained T-cell activity. Bladder cancer is the tenth most prevalent cancer worldwide with suboptimal progression free survival in the locally advanced and metastatic setting. Efficacy of checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC) patients indicates the presence of tumor antigen-specific T-cell activity, and thus, treatment with a costimulatory bsAb as a single agent may elicit a durable and robust anti-tumor response. Here we describe RNDO-564, a novel CD28 x Nectin-4 bispecific molecule. RNDO-564 was developed preclinically with optimal potency to provide robust anti-tumor activity and safety by localizing co-stimulatory activity to the site of the tumor and avoiding super-agonist activity. Methods: High throughput antibody discovery was completed on CD28 and Nectin-4. A panel of agonistic bispecific CD28 antibodies was generated by combining high affinity Nectin-4 binders with CD28 binders of varying potencies using knobs-in-hole technology. Bispecific antibodies were tested for their ability to enhance T-cell mediated cytotoxicity and cytokine release on tumor cell lines expressing varying levels of Nectin-4 in the presence of suboptimal signal 1. Lead candidates were then tested for efficacy using in vivo syngeneic mouse models. Results: Affinity tuning of CD28 agonistic activity was performed by testing a diverse panel of CD28 effector arms to identify optimal costimulatory activity that lacked super agonist activity. One of these CD28 binders was paired with a high affinity Nectin-4 binder to generate RNDO-564. With an affinity tuned CD28 arm and a high affinity Nectin-4 arm driving localization to tumor cells, RNDO-564 exhibited potent and specific cytotoxicity and cytokine release to Nectin-4 expressing tumor cells in vitro. In vivo , RNDO-564 alone and in combination with an anti-PD-1 mAb resulted in dose-dependent tumor growth inhibition in signal 1-proficient syngeneic models, indicating clinical potential for both monotherapy and combination activity. In addition, RNDO-564 was well-tolerated in non-human primates and had normal pharmacokinetics after a single dose infusion. Conclusions: RNDO-564 has a high affinity Nectin-4 binding arm and an affinity-tuned CD28 arm optimized for activity in metastatic bladder cancer. A phase 1 study is planned to evaluate the safety, tolerability, PK/PD, and clinical activity of RNDO-564 alone and in combination with CPI in mUC.

Management strategies and patient outcomes among LPC patients with persistently positive PSA after RP.

Journal of Clinical Oncology Shawn Malone, Christopher J.D. Wallis, Ilias Cagiannos et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.353

353 Background: Patients (pts) with localized high-risk/very high-risk prostate cancer (PCa) have an elevated risk of metastases and Prostate Cancer (PC)-specific death following local therapy. This risk is significantly higher for patients with a persistently elevated PSA (pPSA) after Radical Prostatectomy (RP) We aim to better understand the current management strategies for this population using real world data. Methods: We performed a retrospective population-based cohort study using province-wide linked administrative data from 2010-2022, in Ontario, Canada. Patterns of patient management in the intermediate (IR)/High-/very high risk (h/vHR) LPC patients who underwent RP with persistently elevated PSA≥0.1 ng/ml were analyzed. Results: In this retrospective cohort between 2010-2021, 31,571 patients diagnosed with LPC were identified. Cohorts were stratified by IR (58.2%, n=18,365) and H/vHR (41.8%, n=13,206). Overall, 13493 pts with IH/HvHR received RP as their treatment for LPC, from which 314 pts (Intermediate Risk=127; High-Very high risk=187) had a persistently positive PSA after RP. 46.8% (n=147) of pts with pPSA received RT, 40.4% (n=127) ADT and 21.7% (n=68) RT+ADT as their next line of treatment (p=<.0001; SD=0.880). PSA value after RP and immediately preceding start of next line of therapy was 0.6 ng/ml (Median IQR: 0.2-1.5 ng/ml) in the RT subgroup and 5.8 ng/ml (Median IQR 2.9-10.5 ng/ml) and 0.9 ng/ml in ADT and ADT+RT groups respectively (Median IQR 0.2-4.3 ng/ml; p=<.0001). Median (IQR) time to CRPC was 9 years (7-11.3) in pts without a pPSA and 7.4 years (5.2-10) in patients with a persistent PSA (P=<.0001). Conclusions: Patients who do not achieve a PSA<0.1 ng/ml after radical prostatectomy have a worse prognosis. LPC patients should be monitored closely after RP to identify the sub-population with persistent PSA that could benefit from additional therapies intensified systemic therapies including Androgen Receptor Pathway Inhibitors (ARPIs). Time to progression to CRPC, PC event, and mortality by persistent PSA status among patients with RP. Persistent PSA Label Total No Yes P Value Variable (Sample size) N=14,084 N=13,770 N=314 Time to CRPC n (%) 186 (1.3%) 148 (1.1%) 38 (12.1%) <.0001 Median (IQR), Years 9.1 (7-11.3) 9 (7-11.3) 7.4 (5.2-10) <.0001 Time to PC event n (%) 6,001 (42.6%) 5,744 (41.7%) 257 (81.8%) <.0001 Median (IQR), Years 6.7 (1.9-3.6) 6.8 (1.5-10) 0.8 (0.4-4) <.0001 PSA value before RP (PSA test closest to RP) Median (IQR), (1) ng/ml 6.7 (5.1-9.6) 6.7 (5.0-9.6) 9.0 (5.9-12.8) <.0001

PSA dynamics: Enhancing predictive models in prostate cancer follow-up.

Journal of Clinical Oncology Lydia Ekama, Mariana Borras Osorio, Mohammad Javad Namazi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.424

424 Background: Advances in prostate cancer (PC) care have led to a 98% 10-year survival rate. Prostate Specific Antigen (PSA) is the primary method of follow-up after definitive radiotherapy (RT), with benign PSA ‘bounce’ occurring in up to 30% of patients, causing uncertainty and anxiety. Distinguishing between PSA bounce and biochemical recurrence (BCR) remains challenging. The Phoenix Criteria is the standard definition of BCR since 2006, defined as PSA nadir + 2 ng/dl, but does not consider patient specific information. Our study aims to explore factors associated with bounce and BCR and develop a predictive tool to differentiate between these two events. Methods: PC patients who received RT at our institution between 2006 and 2022 were identified, including only patients with a PSA increase during follow-up. Exclusion criteria included palliative RT, prostatectomy, or insufficient follow-up information. Patients’ clinical data was collected, and PSA increase was classified as bounce or BCR. Variables were compared using Kruskal Wallis or Chi-square. Multivariate logistic regression was performed in the subset of patients with absolute PSA value >2 (n= 581). Results: Of 1783 patients reviewed due to PSA rise after treatment, 694 met the inclusion criteria. There were 213 (30.7%) with PSA bounce and 481 (69.3%) with recurrence. Prior to meeting the Phoenix Criteria, 20 (4.2%) had biopsy-proven recurrence and 18 (3.7%) imaging-proven recurrence. The median delta PSA was 0.8 ng/mL for bounce vs 5 ng/mL for recurrence (p<0.001). The median time from treatment to event was 14.4 months for bounce vs 45.3 months for BCR (p<0.001). Recurrence was significantly associated (p<0.001) with older age at diagnosis, N1 stage, higher risk category, Gleason score, and higher baseline PSA. In the subgroup of patients without ADT, recurrence was associated with a lower median first PSA post-RT (1.9 vs. 2.4, p=0.046) and a lower median nadir before event (0.6 vs. 1.8, p<0.001). Multivariate logistic regression achieved an accuracy of 0.94, with a sensitivity of 0.83, specificity of 0.98, and an area under the curve (AUC) of 0.97. Conclusions: Our results highlight significant differences in clinical factors between bounce and recurrence in post-RT patients. The multivariate logistic regression differentiated the events with 94% accuracy for patients with a rising PSA value >2 subgroup. We highlight the possible improvement that could be accomplished by personalizing a PSA threshold for recurrence versus the Phoenix definition. This tool offers patients and providers a highly specific tool to differentiate between PSA recurrence and bounce, and may reduce stress and unnecessary testing, or help diagnosis recurrence faster. Next steps include prospective validation of the model to assess the impact on clinical practice costs, patient experience, and cancer outcomes.

Further Optimizing Care of Patients With Operable Hormone Receptor–Sensitive Breast Cancer

Journal of Clinical Oncology Alexandra Thomas, Erica L. Mayer, Angela DeMichele et al. Feb 10, 2025 DOI: 10.1200/jco.24.01080

Harmonized global collaborations are crucial to improving outcomes in hormone sensitive operable breast cancer.

Use of geospatial analysis with multiplex immunofluorescence to analyze tumor immune microenvironment patterns and prognosis in penile cancer.

Journal of Clinical Oncology Adnan Nazir Fazili, Keerthi Gullapalli, Jasreman Dhillon et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.12

12 Background: Previous studies utilizing multiplex Immunofluorescence (mIF) have described cell density patterns of immune exhaustion implicating both innate and adaptive immune system components across varying stages of penile squamous cell carcinoma (PSCC). Here we studied geospatial clustering patterns of various immune effector cells within the tumor immune microenvironment (TIME). Methods: Tissue microarray (TMA) was constructed for 57 cases of invasive PSCC and immunostained for CD20, CD3, CD4, CD8, CD45RO, CD68, CD206, CD163, NKp46, FOXP3 using OPAL TM 7 kit (AKOYA Biosciences). Areas of tumor and stroma were identified using an image analysis system (InForm 2.2.4). Spatial analysis and co-clustering of cell phenotypes was performed using Ripley’s K. Survival curves were determined using Kaplan Meier method and tested using logrank and cox regression. Univariate and bivariate analysis describes co-clustering and proximity to tumor cells, respectively. Results: 57 PSCC patients (median age 60, [IQR (interquartile range) 31-92]); 60% HPV negative, and 31/57 with pN+ had mIF analysis. A high clustering pattern of CD68+, a general marker for macrophages, was associated with a significant OS benefit on univariate analysis (162 vs 36 mos, p=0.006) and an OS, RFS, and CSS benefit on bivariate analysis (84 vs 27 mos; NA vs 14 mos; NA vs 27 mos p=0.007, 0.014, 0.001). High clustering of CD3+CD4+, a marker for T-helper-lymphocytes, within the tumor and the tumor-stroma interface was associated with an OS benefit on bivariate analysis (84 v 20 mos, p=0.009). Low intra-tumoral clustering of CD68+CD163+, marker for M2 protumor macrophages, was associated with improved RFS on bivariate analysis (NA v 15 mos, p=<0.01). Low clustering of CD68+CD163+ in HPV+ patients was associated with a CSS benefit compared to high clustering in HPV- patients (p=0.024). High versus low clustering of CD68+CD163+ was inconsequential in HPV- patients (p=0.66).Overall, low intratumoral clustering pattern of FOXP3+, a marker for regulatory immune-suppression, was associated with an improved CSS on bivariate analysis (p=0.017). Low clustering of FOXP3+ in HPV+ patients was associated with an improved CSS versus low clustering of FOXP3+ in HPV- patients (p=0.041). Conclusions: Spatial analysis shows that proximity of CD68+ and CD3+CD4+, a general marker for macrophages and T-helper cells, to tumor cells has a positive impact survival in PSCC. Interestingly, proximity of protumor M2 macrophages to cancer cells confers a survival benefit specifically in HPV+ tumors and has no impact on survival in HPV- tumors. Decreased intratumoral FOXP3+ activity, a marker for regulatory immune-suppressive T cells, shows a preferential survival benefit in in HPV+ tumors. These findings point to diverging tumorigenic pathways related to HPV status that may be attributable to their poorer prognosis.

Chromosomal instability in tumor suppressor genes–altered prostate cancer.

Journal of Clinical Oncology Marta Garcia de Herreros, Natalia Jimenez, Joan Padrosa et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.226

226 Background: Metastatic prostate cancer (PC) accumulates significant genomic alterations as the disease progresses, exhibiting the highest levels of chromosomal instability (CIN) among all metastatic tumors (Bakhoum, Nature 2018). Furthermore, tumor suppressor genes (TSG; RB1 , PTEN and TP53 ) are frequently altered in metastatic PC and are associated with adverse outcomes. Here, we aim to investigate CIN in metastatic hormone-sensitive PC (mHSPC) harbouring alterations in TSG. Methods: TSG and whole transcriptome gene expression was assessed by nCounter platform (N=354) and RNA-seq (N=60) in mHPSC samples, respectively. TSG low was considered when ≥2 out of 3 TSG presented low expression of a previously stablished cut-off, and TSG wt in the remaining cases. Differential gene expression analysis between TSG low vs TSG wt tumors of our RNA-seq cohort (N=60) and TCGA cohort (N=333) was performed. Differential expressed genes (DEGs) were considered if FDR <0.05 and log2FoldChange (LFC)>0.5. DEGs were correlated with castration-resistance PC-free survival (CRPC-FS) and overall survival (OS) by Cox analysis. CIN gene signatures were obtained from literature and the rest of Hallmark signatures from MSigDB. Results: In our cohort of mHSPC patients treated with androgen deprivation therapy + docetaxel, TSG low tumors (16.7%) displayed higher levels of CIN compared with TSG wt (CIN25 normalized enrichment score [NES] 2.13, p<0.001 and CIN70 NES 2.54, p<0001). Cell cycle and DNA-repair signatures were also overexpressed in TSG low tumors, contrasting with a low expression of androgen receptor pathway. Results were validated in the TCGA cohort, where TSG low presented also overexpression of CIN signatures. In our RNA-seq cohort, we found 22 DEGs associated with CIN (29.3% of the total DEGs) in TSG low tumors compared with TSG wt . 51 genes were significantly correlated with CRPC-FS in a multivariate analysis and 16 of them (31,3%) were CIN-associated genes. Among these genes, 5 encode proteins that are targetable for metastatic PC, with specific inhibitors already developed: BUB1 (LFC 1.06, FDR 0.034), CDC7 (LFC 12.4 FDR 0.003), KIFC1 , (LFC 11,7, FDR 0.01), PLK1 (LFC 1.08, FDR <0.001) and WEE1 (LFC 0.79, FDR 0.011). Conclusions: TSG-altered mHSPC tumors harbor high levels of CIN, and differentially expressed CIN-associated genes could potentially be targets in mHSPC.

Modeling survival outcomes of KEYNOTE-564 with standard of care control arm treatment: A simulation study.

Journal of Clinical Oncology Fady Ghali, Syed N. Rahman, Spencer James Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.517

517 Background: The KEYNOTE-564 study, reporting improved overall survival (OS) with use of adjuvant checkpoint inhibitor (CPI), pembrolizumab, following surgery for renal cell carcinoma (RCC) suffers from a common challenge: a large portion of the control arm received non-standard of care (nSOC) subsequent therapy upon progression (in this case dual CPI or CPI + tyrosine kinase inhibitor [TKI]), thus underestimating survival in this group. We sought to model the survival of KEYNOTE-564 control group patients had they received CPI/TKI per current standard of care (SOC) to more accurately assess this intervention. Methods: Data were extracted from the Kaplan-Meier plots as published in KEYNOTE-426 and KEYNOTE-564. Patient-level survival data were simulated using an iterative process to adjust the censored and event rates to ensure consistency with published reference survival curves derived from KEYNOTE-426. Thus, these measures estimate a counterfactual survival parameter for the KEYNOTE-564 control group based on results from the KEYNOTE-426 study to approximate the expected increase in survival probability if the percent of control patients which received nSOC therapy had received SOC. The analytical process was conducted using R version 4.3.1, with MASS, splines, survival, dplyr, and survminer packages. Results: A total of 52% (N = 109) of patients in the control arm of KEYNOTE-564 that progressed did not receive CPI in the first-line setting. Based on KEYNOTE-426, we estimated a one-year mortality risk of 9.5% for those receiving axitinib-pembrolizumab versus 19.8% in those receiving TKI alone, equating to a 10.3% attributable risk between these arms. When KMA was performed on extracted data where that proportion of patients in the control arm were simulated to have avoided death on an annual basis distributed randomly across five years (n = 51 patients), the re-estimated, unadjusted hazard ratio in this was 1.41 (0.93 to 2.14). As a sensitivity analysis, we conducted this model with a survival parameter of 5% instead of 10% annual mortality risk, resulting in an unadjusted hazard ratio of 0.88 (0.61 to 1.28), and with 2.5% (unadjusted HR 0.72 (0.50 - 1.02). Conclusions: We report and validate method for modeling appropriate subsequent therapy for clinical trials where nSOC treatment in the control group limits the interpretation of their conclusions. In a simulation correcting for the under-estimated survival in the control arm of KEYNOTE-564, the reported survival benefit of adjuvant CPI may not be statistically durable.

Spatial analysis of the immune microenvironment and identification of phenotypes of prognostic significance in penile squamous cell carcinoma (PSCC).

Journal of Clinical Oncology Keerthi Gullapalli, Justin Miller, Adnan Nazir Fazili et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.13

13 Background: Advanced penile cancer is a rare but aggressive malignancy. Over 70% of patients with bulky metastases relapse or have primary refractory disease with current treatments. Immunotherapy represents a promising modality, but response rates remain low. While prior studies explored single immune factors within the tumor microenvironment (TME), understanding complex interactions between T cells and macrophages and in relation to the tumor cells is crucial to best characterize the TME. Methods: We performed multiplex immunofluorescence (mIF) on 59 PSCC tissues obtained from MD Anderson to analyze expression of 12 key immune cell markers (CD3, CD8, CD68, CD86, CD206, CD163, ARG, CSF1R, MHC-II, PD-1, PD-L1). Spatial analysis and co-clustering of cell phenotypes was performed using Ripley’s K. Overall (OS), recurrence free (RFS), and cancer specific survival (CSS) curves were determined using Kaplan Meier method and tested using logrank and cox regression models. Results: The median age was 60 (IQR 24-86) and majority were HPV negative (64%). High densities and clustering of cytotoxic CD8+ T cells and CD68+ tumor associated macrophages (TAMs) were each associated with improved OS (126 vs 61 months, p= 0.03; 140 vs 61 months, p= 0.04, respectively]. Conversely, high densities of antigen-experienced CD8+PD-1+ cytotoxic T cells and antigen-experienced CD68+PD-1+ macrophages were associated with worse OS [HR 1.44 (1-2.05), p= 0.04 and HR 1.48 (1.04-2.12), p=0.03 respectively], PFS [HR 1.45 (1.03-2.05), p= 0.03 and HR 1.53 (1.06-2.19), p= 0.02 respectively ] and CSS [HR 1.52 (1.03-2.24), p= 0.03 and HR 1.63 (1.12-2.36), p= 0.01 respectively]. Clustering of CD86+ M1 macrophages was associated with improved OS (104.5 vs 29.1 months, p=0.02), while clustering of CD163+ and CD206+ M2 macrophages correlated with decreased OS (67.8 vs 199.7 months, p=0.03; 100.6 vs NA months, p=0.01 respectively). Bivariate analysis revealed improved OS associated with co-clustering of CD8+ T cells with TAMs (104 vs 42 months, p=0.03). Similarly, co-clustering of CD8+T cells with CK+ tumor cells was associated with improved OS (140 vs 61 months; p=0.02). While co-clustering of CD86+ M1 macrophages to cytokeratin (CK+) tumor cells correlated with improved OS (126 vs 42 months, p=0.03), co-clustering of CD 206+ M2 macrophages to CK+ tumor cells associated with poor RFS (48 vs NA months, p=0.03). Co-clustering of antigen experienced T cells with TAMs was also associated with decreased RFS (29 vs NA months, p =0.03). Conclusions: Using spatial analysis, we showed that interaction between T cells and macrophages impact clinical outcomes in PSCC. High densities and proximity of CD8+ T cells and M1 macrophages, and low levels of antigen experienced T cells and macrophages were associated with improved survival in PSCC.

Impact of adjuvant intraarterial chemotherapy on survival for patients with stage IIIA-IIIB bladder urothelial carcinoma after radical cystectomy: An open-label, prospective, randomized clinical trial.

Journal of Clinical Oncology Zhaohui Zhou, Lijuan Jiang, Kai Yao et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.772

772 Background: The aim of this trial was to evaluate the survival benefit of adjuvant intraarterial chemotherapy (IAC) in patients who received radical cystectomy (RC) and pathologically confirmed stage IIIA-IIIB bladder urothelial carcinoma. Methods: This was a multicenter, randomized study. Patients with stage IIIA-IIIB (pT3-4 or positive node) disease after RC were randomly assigned (1:1) to the IAC group or the observation group. Adjuvant IAC with cisplatin and gemcitabine (GC) was performed through a percutaneous catheter system. The GC regimen consisted of gemcitabine 800 mg/m² and cisplatin 25 mg/m² on days 1, 8, and 15 every 28 days for three cycles. The primary endpoint was recurrence-free survival (RFS). The secondary endpoint was overall survival (OS). The trial was designed to detect a 20% improvement in 5-year RFS, from 35% to 55% in IAC group (HR: 0.57), with a two-sided significance level of 0.05 and 80% power. Considering a 10% loss to follow-up, the calculated sample size was 212 patients (106 for each arm), to be accrued over 7 years. Survival curves were estimated using the Kaplan–Meier method and compared using the log-rank test. Results: The interim analysis was cancelled in the 8th year after enrolling 186 patients due to poor accruals. Based on the actual accrual interval, the sample size was recalculated, reducing the target to 184 patients with approximately 100 events. One hundred eighty-six patients were randomly assigned to two arms (93 in the IAC group and 93 in the observation group). The median age was 63 years (quartiles 57-70), with 169 (91%) of the 186 patients being male. Among the patients, 110 (59%) had pT3 disease, and 51 (27%) had pT4 disease. Lymph node involvement (LNI) was 54.3% in total, and was comparable between the two groups (54% vs. 55%). With a median follow-up of 77.9 months, 106 (57%) patients experienced recurrence (48 in the IAC group and 58 in the observation group). In the intention-to-treat (ITT) population, IAC significantly prolonged RFS (HR: 0.66, 95% CI: 0.45-0.96; p = 0.031), with a 5-year RFS of 47.7% (95% CI: 38.0%-60.0%) in the IAC group and 35.2% (95% CI: 26.5%-46.8%) in the observation group. OS was better in the IAC group as compared with the observation group, although the improvement reaches statistical significance only in per-protocol population (PP) (HR: 0.60, 95% CI: 0.39-0.94; p = 0.025). Grade 3/4 treatment-related adverse events occurred in 34.6% of the patients, and a significantly lower incidence of grade 3/4 leukopenia (9.0%) and thrombocytopenia (3.9%) was observed when compared to intravenous chemotherapy. Conclusions: Adjuvant IAC significantly improved RFS in patients with stage IIIA-IIIB bladder urothelial carcinoma, with a good safety and tolerability profile. OS was also significantly improved in the IAC group among the PP population. Clinical trial information: NCT01627197 .

Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP): A comparison of enzalutamide vs abiraterone acetate.

Journal of Clinical Oncology Alicia K. Morgans, Yangruijue Ma, James C. Jackson et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.131

131 Background: Whether treatment with androgen receptor pathway inhibitors (ARPIs) with distinct mechanisms of action and central nervous system (CNS) penetration has distinct effects on cognitive function or quality of life (QOL) has been incompletely described. We compared cognitive function and QOL between patients with advanced prostate cancer treated with abiraterone acetate (AA) or enzalutamide (ENZ) in US patients enrolled from one of six sites. Methods: Patients with metastatic hormone sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) who were initiating treatment with enzalutamide or abiraterone acetate (AA) were prospectively enrolled. Patients underwent cognitive testing (written and computer-based) and completed patient reported outcome measures (PROMs) at baseline, 3, 6, and 12 months. The primary endpoint compared median changes in CANTAB computer-assessed cognitive function between groups at 3 months, and secondary endpoints included comparison of longitudinal cognitive function and PROMs. Results: In total 74 of planned 100 participants enrolled: 51 treated with AA and 23 treated with ENZ. Participants were approximately 90% White race, with slightly younger age (70 vs 74 years, p = 0.5) and greater education status (16 vs 13 years, p = 0.2) among AA vs ENZ patients, respectively. Baseline CANTAB and PROs were similar between groups and there were not clinically meaningful changes over time (Table). Median change in all CANTAB module scores was similar between groups at 3, 6 and 12 months, without clinically meaningful change over time (Table). Conclusions: No measurable changes were identified on cognitive testing between baseline and 3 months within or between treatment groups, and QOL decreased minimally over time and was similar between treatment groups despite different effects of treatment in the CNS. Reasons may include lack of difference in effect between agents or an inability to detect differences with existing measures in an all-comers population not enriched for patients most vulnerable to cognitive change. Further analyses of genetic factors and functional MRI studies associated with cognitive change are ongoing. Clinical trial information: NCT03016741 . Example cognitive test and PROM. Baseline 3 Month 6 Month 12 Month AA, N = 48 1 Enz, N = 20 1 p-value 2 AA, N = 35 1 Enz, N = 17 1 p-value 2 AA, N = 34 1 Enz, N = 15 1 p-value 2 AA N = 25 1 Enz, N = 13 1 p-value 2 PAL -0.53 (-1.08, 0.07) -0.44(-0.88, 0.16) 0.7 0.00 (-0.58, 0.63) -0.46(-0.65, 0.29) 0.2 0.00(-0.58, 0.65) 0.27(-0.47, 0.78) 0.7 0.00(-0.23, 0.23) 0.00(-0.29, 0.50) 0.9 FACT Cog 128.0(111.0, 136.8) 132.0 (120.5, 138.5) 0.5 -9.0(-17.5, 2.0) -2.0(-16.2, 3.5) 0.6 -2.0(-13.0, 3.5) -3.0(-16.0, 4.0) >0.9 -7.5(-17.5, 2.2) -1.2 (-6.9, 4.8) 0.4 1 Median (IQR); 2 Wilcoxon rank sum test.

A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology Wassim Abida, Yu Chen, Deaglan Joseph McHugh et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps290

TPS290 Background: Androgen receptor pathway inhibitors (ARPIs) are standard life-prolonging therapies for patients with metastatic castration-resistant prostate cancer (mCRPC), but patients ultimately progress on these agents. Resistance has been shown to occur in part via lineage plasticity mediated by increased activity of kinases including JAK1 and FGFR. Preclinical studies have shown that ARPI sensitivity can be restored by inhibiting these kinases. Tinengotinib is an orally bioavailable, potent multi-kinase inhibitor that targets JAK1 and receptor tyrosine kinases (FGFRs, VEGFRs). We hypothesize that in patients with mCRPC who are progressing on ARPIs, the addition of tinengotinib will restore sensitivity to ARPIs and result in objective responses. Methods: This is a multi-center, phase 1b/2 study of tinengotinib plus either abiraterone/prednisone or enzalutamide in patients with mCRPC. Eligible patients must be on ongoing therapy with abiraterone/prednisone or enzalutamide started at least 90 days prior to study participation consent and progressing by Prostate Cancer Working Group 3 (PCWG3) criteria. Tinengotinib will be added to abiraterone/prednisone or enzalutamide at the time of progression. Phase 1b (N = up to 24) uses a 3+3 de-escalation schema to assess the safety and tolerability of tinengotinib with either abiraterone/prednisone or enzalutamide. The starting dose of tinengotinib will be 10 mg PO QD, with the possibility of de-escalation to 8 mg PO QD if a combination is not tolerated. Phase 2 employs a two-stage Simon minimax design; patients will be enrolled to evaluate the safety and efficacy of the recommended phase 2 dose (RP2D) of tinengotinib with abiraterone acetate/prednisone or enzalutamide (N = 32). Since abiraterone acetate and enzalutamide target the same pathway, response will be evaluated in combination in the signal-seeking phase 2 portion of the study. As of October 2024, 2 patients have been enrolled in phase 1b across 1 site. Enrollment for phase 2 is expected to begin in January 2025. Clinical trial information: NCT06457919 .

Reduction of systemic chemotherapy by primary retroperitoneal lymph node dissection in low volume metastatic seminoma.

Journal of Clinical Oncology David Pfister, Pia Paffenholz, Constantin Rieger et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.626

626 Background: Still, standard treatment of low-volume metastatic semimoma is either systemic chemotherapy or radiotherapy. Both options are associated with significant acute and long-term toxicities including mortality due to secondary malignancies in long-term follow-up. We calculated the number of potentially unnecessary chemotherapy cycles per hundred patients undergoing primary RPLND or Chemotherapy. Methods: In long-term follow-up of the COTRIMS-trial, 34 (12%) patients developed outfield relapses after a median follow-up of 41 months. All relapsing patients were cured by salvage PEB-chemotherapy. The base of our calculation are 12 recurrences on 100 Pts compared to 100 patients receiving chemotherapy upfront. Short term side effects of chemotherapy are from a historic patient cohort. Results: 12 relapsing patients received 36 cycles of PEB instead of 300 cycles of chemotherapy if given as first-line treatment. Significant PEB-associated acute toxicities mostly affect haematoxicity with neutropenia in 4 and 37 patients, resp., and febrile neutropenia in 1.7 and 14 patients, resp.. Based on our previous studies (Paffenholz P et al., World J Urol 2019; 37:1907), thrombembolic venous or arterial events are expected in 1.2 and 0.8 , resp. versus 10 and 7 patients, resp.. Therapy associated mortality would be expected in 0.2 and 2 patients, resp.. No data on long-term toxicities are available. Conclusions: All patients with relapses after primary RPLND can be cured by salvage chemotherapy. The number of chemotherapy cycles can be reduced by 88% without impairing oncological efficacy if surgery is performed in an experienced reference center. Thus overall acute toxicity rate affecting patients quality of life and even treatment associated deaths can be reduced dramatically. Although the reduction of long-term toxicities associated with cytotoxic therapy cannot be anticipated today, we strongly recommend to include primary nsRPLND in the therapeutic armentarium of clinical stage IIA/B seminomas.

Real-world effectiveness and treatment (tx) patterns in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in Japan: Results from the JAVEMACS chart review study.

Journal of Clinical Oncology Hiroshi Kitamura, Takashi Kobayashi, Go Kimura et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.701

701 Background: Avelumab 1LM was approved in Feb 2021 in Japan based on results of the JAVELIN Bladder 100 phase 3 trial, which showed prolonged overall survival (OS) in pts with la/mUC that had not progressed with platinum-based chemotherapy (PBC). We report the primary analysis from a chart review study of pts with la/mUC receiving avelumab 1LM in Japan. Methods: This multicenter retrospective study reviewed medical charts of pts with la/mUC who received 1L PBC and started avelumab 1LM between Feb 2021 and Dec 2023. Pt characteristics, effectiveness, and tx patterns were analyzed. Results: The study included 354 pts. At data cutoff (Jun 2024), median observation period was 14.6 mo from start of avelumab and 19.8 mo from start of 1L PBC. At the start of avelumab, median age was 73 y (range, 43-93), 261 pts (73.7%) were male, and ECOG PS was 0 in 287 (81.1%), 1 in 57 (16.1%), and ≥2 in 6 (1.7%). Primary tumor location was bladder in 179 (50.6%) and renal pelvis/ureter in 170 (48.0%). 1L PBC was gemcitabine (gem) + cisplatin (cis) in 198 (55.9%) and gem + carboplatin (carbo) in 117 (33.1%); 101 pts (28.5%) were cis eligible, and 187 (52.8%) were cis ineligible/platinum eligible. Number of PBC cycles was 1-3 in 71 (20.1%), 4 in 206 (58.2%), 5-6 in 61 (17.2%), and ≥7 in 16 (4.5%). Median time from start of PBC to start of avelumab was 19.1 wk (IQR, 15.4-24.1). At last follow-up, 68 (19.2%) were still receiving avelumab, 202 (57.1%) had received second-line (2L) tx, and 84 (23.7%) had received third-line (3L) tx. The most common 2L and 3L tx were enfortumab vedotin (EV) in 134 (66.3%) and 25 (29.8%), cis/carbo + gem in 41 (20.3%) and 13 (15.5%), and pembrolizumab in 17 (8.4%) and 37 (44.0%), respectively. OS analyses are shown in the Table. Conclusions: Avelumab 1LM seems to provide long-term OS benefits in this population of pts with la/mUC that had not progressed with 1L PBC in clinical practice in Japan. Adequate 1L PBC selection may result in long-term OS regardless of cis eligibility. Although pts were not resistant to PBC, 2L EV was more common than 2L PBC after avelumab 1LM, highlighting the evolving tx landscape. OS, median (95% CI), mo OS from start of avelumab 1LM OS from start of 1L PBC* OS from start of 2L Overall (N=354) 31.8 (24.6-NE) 38.9 (35.6-NE) - 1L PBC Gem + cis (n=198) NE (31.2-NE) 40.8 (37.6-NE) - Gem + carbo (n=117) 24.3 (19.5-30.6) 28.9 (23.9-NE) - Platinum eligibility Cis eligible (n=101) 31.2 (20.0-NE) 38.9 (26.9-NE) - Cis ineligible/platinum eligible (n=187) 31.8 (22.6-NE) 38.7 (26.3-NE) - 2L analysis set (n=202) 24.3 (20.2-31.2) 31.3 (26.3-38.7) 15.1 (13.2-20.1) EV (n=134) 31.8 (20.6-NE) 37.2 (26.6-60.6) 17.8 (11.9-NE) PBC (n=42) 23.5 (16.9-NE) 26.9 (22.2-NE) 15.1 (11.6-NE) NE, not estimable. *Population included only pts without disease progression after 1L PBC and survived to receive avelumab 1LM.

Initial biopsy results of the PATROL study: Prostate screening for people with inherited risk of developing aggressive prostate cancer.

Journal of Clinical Oncology Daniel Lee, Caitlin Orr, Kara N. Maxwell et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.426

426 Background: Germline pathogenic variants (gPV) in prostate cancer (PrCa) risk genes are associated with aggressive disease and worse outcomes. However, the degree of risk by gene, the optimal PSA thresholds for biopsy, and the utility of MRI for screening are not well characterized. Therefore, we developed the PATROL study (clinicaltrials.gov: NCT04472338), a prospective multi-center early detection study for people at risk for PrCa due to variants in PrCa risk genes. Here, we report initial biopsy results of participants enrolled to date. Methods: The primary endpoint of PATROL is to determine the positive predictive value of predefined age-adjusted PSA thresholds and prostate-specific imaging for biopsy. Key eligibility criteria include: people ≥40y with prostates that carry a gPV in one or more of 13 PrCa risk genes. Participants undergo prostate biopsy per age-adjusted PSA threshold recommendations: PSA >1.0 ng/mL if <50y; PSA >1.5 ng/mL if 50-59y; PSA >2.0 ng/mL if ≥60y). Patients are encouraged to receive a prostate MRI at baseline and/or within one year of biopsy. Clinically significant prostate cancer (csPrCa) was defined as ≥Grade Group 2 (GG2). Results: Of 291 patients enrolled in PATROL at the time of this analysis, gPVs were most frequent in BRCA2 (n=141, 48%) and BRCA1 (n=71, 24%). 55 patients have undergone biopsy, with a median age of 57 (IQR 52-66) and median PSA of 2.2 (IQR 1.2-4.4) at time of biopsy. Of these biopsies, 10 (18.2%) had GG1 disease, and 11 (20%) had csPrCa. Of the men with csPrCa, six (55%) had PSA above the PATROL age-adjusted threshold but less than standard-of-care 4 ng/ml. An additional three (27%) patients had abnormal MRI with normal age-adjusted PSA. All 11 men with csPrCa underwent definitive treatment, while 7 of the men (70%) with GG1 initiated active surveillance. In a logistic regression model adjusting for age, gPV and PSA level, having a PIRADS 4 or 5 lesion was associated with csPrCa (OR 34.3, p=0.001). Conclusions: Screening gPV carriers using age-adjusted PSA and MRI resulted in 20% of biopsies detecting clinically significant prostate cancer. Conventional PSA thresholds for biopsy would have missed more than 80% of the clinically significant prostate cancer in men with gPV. Ongoing enrollment, site expansion and longer-term follow-up in this study, along with other studies will help improve the early detection of significant prostate cancer among men with gPV. Clinical trial information: NCT04472338 .

Real-world comparison of cabazitaxel vs. 177-lutetium-PSMA radioligand therapy in metastatic castration resistant prostate cancer.

Journal of Clinical Oncology Mike Wenzel, Florestan Koll, Benedikt Hoeh et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.70

70 Background: 177-Lutetium Prostate-specific membrane antigen (Lu-PSMA) therapy is under current scientific investigation and aims to become an established part in treatment of metastatic castration resistant prostate cancer (mCRPC). However, real-world evidence in treatment comparison is scant. Methods: We relied on the FRAMCAP database and compared cabazitaxel vs. Lu-PSMA therapy in mCRPC patients regarding progression-free (PFS) and overall (OS). Sensitivity analyses addressed 2 nd to 4 th line mCRPC patients to approximate current Phase-III patient selection criteria. Results: Of 373 mCRPC patients, 14% received cabazitaxel vs. 65% Lu-PSMA vs. 21% both. Patients undergoing Lu-PSMA therapy were significantly older (median 72 vs. 66 years, p<0.01) and displayed a higher proportion of ECOG ≥2 (12 vs. 5.0%, p=0.1), relative to cabazitaxel patients. Rates of PSA50 were 32% vs. 0% for Lu-PSMA vs. cabazitaxel. In outcome analyses, significant superior median PFS was observed for Lu-PSMA vs. cabazitaxel (13.4 vs. 7.1 months, p<0.001), even after multivariable adjustment (HR: 0.38, p<0.001). Regarding OS, rates also significantly differed with median OS of 14.7 vs. 16.5 vs. 29.6 months for cabazitaxel vs. Lu-PSMA vs. both treatments (p<0.01). In sensitivity analyses of 2 nd to 4 th line mCRPC, PFS rates and median OS rates for cabazitaxel vs. Lu-PSMA vs. both therapies qualitatively remained the same compared to the entire cohort. Conclusions: In real-world setting, Lu-PSMA provides significantly better PFS and qualitatively better OS rates compared to cabazitaxel chemotherapy and should therefore be considered as a valuable treatment option for advanced mCRPC patients according to the EMA-approval. Characteristics of 296 metastatic castration resistant prostate cancer (mCRPC) patients stratified according to treatment of cabazitaxel vs. 177 - Lutetium- prostate-specific membrane antigen radioligand therapy (Lu-PSMA). Characteristic N Overall,N = 296 1 CabazitaxelN = 52 (18%) 1 Lu-PSMA,N = 244 (82%) 1 p-value 2 Age at mCRPC, years 192 71 (64, 76) 66 (58, 71) 72 (66, 78) <0.001 PSA at m CRPC, ng/ml 141 18 (6, 72) 63 (12, 144) 15 (6, 64) 0.044 Number of CRPC lines 296 3 (2, 4) 4 (3, 5) 3 (2, 4) <0.001 Cycles systemic treatment 229 3 (2, 6) 5 (3, 6) 3 (2, 6) 0.031 PSA response, % 39 20 (0, 66) 15 (0, 23) 25 (0, 68) 0.3 PSA50 39 11 (28%) 0 (0%) 11 (32%) 0.3 PSA90 39 5 (13%) 0 (0%) 5 (15%) 0.9 ECOG status at mCRPC 109 0.10 0 52 (48%) 14 (70%) 38 (43%) 1 45 (41%) 5 (25%) 40 (45%) >=2 12 (11%) 1 (5%) 11 (12%) Cardiovascular disease 183 66 (36%) 13 (35%) 53 (36%) 0.9 Gleason Score 8-10 259 181 (70%) 39 (80%) 142 (68%) 0.10 De Novo mHSPC 290 161 (56%) 33 (63%) 128 (54%) 0.2 High volume mHSPC 146 99 (68%) 24 (73%) 75 (66%) 0.5 Metastatic sites at mCRPC 130 0.8 M1a 14 (11%) 3 (13%) 11 (10%) M1b 104 (80%) 20 (83%) 84 (79%) M1c 12 (9%) 1 (4%) 11 (10%) Treatment mHSPC 126 0.034 ADT mono 25 (20%) 4 (20%) 21 (20%) ARSI 58 (46%) 4 (20%) 54 (51%) Docetaxel 34 (27%) 10 (50%) 24 (23%) Triplet 3 (2%) 1 (5%) 2 (2%) Other 6 (5%) 1 (5%) 5 (5%) Treatment 1st line mCRPC 296 <0.001 ADT mono 29 (10%) 6 (12%) 23 (9%) Chemotherapy 53 (18%) 19 (37%) 34 (14%) Lu-PSMA 28 (10%) 0 (0%) 28 (11%) ARSI 163 (55%) 26 (50%) 137 (56%) PARPi +/- ARSI 1 (0.3%) 0 (0%) 1 (0.4%) Radium 20 (7%) 0 (0%) 20 (8%) None/Other/NA 2 (1%) 1 (2%) 1 (0.4%) Treatment 2nd line mCRPC 296 <0.001 Chemotherapy 69 (23%) 27 (52%) 42 (17%) Lu-PSMA 73 (25%) 0 (0%) 73 (30%) ARSI 114 (39%) 25 (48%) 89 (36%) PARPi+/- ARSI 5 (2%) 0 (0%) 5 (2%) Radium 13 (4%) 0 (0%) 13 (5%) None/Other/NA 22 (7%) 0 (0%) 22 (9%) 1 Median (IQR); n (%). 2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-square test. PSA: Prostate-specific antigen, ECOG: Eastern Cooperative Oncology group, mHSPC: metastatic hormone-sensitive prostate cancer, ADT: Androgen deprivation therapy, ARSI: Androgen receptor signaling inhibitor, PARPi: poly-(ADP-ribose)-polymerase inhibitors, NA: Unknown.

Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.

Journal of Clinical Oncology Neeraj Agarwal, Michael Thomas Schweizer, Elena Castro et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps288

TPS288 Background: Resistance to androgen receptor (AR) pathway inhibitors (ARPI; e.g., abiraterone, enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC) may be driven by preservation of AR signaling through various mechanisms. Enhancer of zeste homolog 2 (EZH2) is implicated in the pathogenesis of prostate cancer and ARPI resistance. Combining ARPI with therapies that modulate alternative signaling pathways, including epigenetic modifiers such as EZH2, could be a promising treatment approach to overcome resistance. Mevrometostat (PF-06821497) is a potent and selective small molecule EZH2 inhibitor. Results from the dose-escalation period of a phase 1 study (NCT03460977) showed promising activity for mevrometostat combined with enzalutamide, with a manageable adverse-event profile in abiraterone-exposed patients with mCRPC (Schweizer MT, et al. J Clin Oncol . 2024;42(16_suppl):5061). The current trial aims to evaluate radiographic progression-free survival (rPFS), overall survival (OS), and safety of mevrometostat plus enzalutamide compared with standard of care in patients with mCRPC previously treated with abiraterone. Methods: MEVPRO-1 (NCT06551324) is a global, open-label, phase 3 trial in patients with mCRPC aged ≥18 years with progression on/after ≥12 weeks abiraterone, castration testosterone levels ≤50 ng/dL, ECOG performance status 0–2, and life expectancy ≥6 months. Approximately 600 patients will be randomized 1:1 to receive mevrometostat (875mg BD with food) with enzalutamide (160mg QD), or physician’s choice of enzalutamide (160mg QD) or docetaxel (75mg/m 2 intravenously every 21d). Randomization will be stratified by previous docetaxel in metastatic castration-sensitive setting, physician’s choice of comparator (enzalutamide/docetaxel), and presence of hepatic metastases. The primary endpoint is BICR-assessed rPFS per RECIST 1.1 (soft tissue) and PCWG3 (bone) assessed by blinded central radiology review. Key secondary endpoint is OS. Secondary endpoints include anti-tumor activity, safety, pharmacokinetics, ctDNA, and patient-reported outcomes. Stratified log-rank P -values, HRs, and 95% CIs will be estimated using a stratified Cox proportional hazard model, and Kaplan–Meier analysis will summarize time-to-event endpoints. Clinical trial information: NCT06551324 .

Association between proto-oncogene N-RAS transcript level and overall survival in node-negative muscle-invasive urothelial bladder carcinoma.

Journal of Clinical Oncology Donghyun Kim, Bilal G. Rahim Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.820

820 Background: Prognostication of urothelial bladder carcinoma relies on clinicopathologic factors including histology, TNM stage and genomic profiles. The prognostic value of tumor subtyping based on gene expression signature clustering has been proposed, but their clinical value remains uncertain. Here, we retrospectively review node-negative muscle-invasive urothelial bladder carcinoma RNA-Seq data and demonstrate that “low” mRNA expression of proto-oncogene N-RAS is associated with significantly superior overall survival (OS). Methods: The Cancer Genome Atlas (TCGA) Pan-Cancer project batch-corrected primary tumor RNA-Seq expression profiles of 114 urothelial bladder carcinoma cases (pT2-4a pN0 M0, n=97; any pT pN1 M0, n=17) and their associated clinical data were retrieved from the cBioPortal. Cohort median was used as a reference to determine “high” vs. “low” transcript levels of N-RAS gene. Log-rank Kaplan-Meier was performed for survival analysis. Two-tailed Mann-Whitney test was performed for group comparison. Results: In node-negative disease group, “low” N-RAS expression (n=58) was associated with significantly superior 5-year OS compared to patients with “high” N-RAS expression (n=39) with hazard ratio (HR) for death at 0.41 (95% CI 0.19-0.86, p=0.007). N-RAS expression-associated differential OS was independent from age group (≥67 vs. <67), gender, T stage (T2 vs. T3-4a), cisplatin-based chemotherapy exposure or underlying TP53, RB1, FGFR3, RAS mutation. However, in patients with “low” N-RAS expression the 5-year OS of those who received cisplatin-based chemotherapy (n=5) was significantly superior compared to those who did not (n=53) with HR for death at 0.26 (95% CI 0.07-0.98, p=0.047). “High” N-RAS expression group was associated with higher CD274 (PD-L1) mRNA expression (x3.9 higher median value, p<0.0001) and larger portion of patients with ≥10 mut/Mb tumor mutational burden (40% vs. 23%) compared to “low” N-RAS expression group. In node-positive disease group, N-RAS expression-dependent differential OS was not present. Conclusions: In node-negative muscle-invasive urothelial bladder carcinoma, “low” N-RAS expression was associated with superior OS which was most pronounced in patients who received cisplatin-based chemotherapy. “High” N-RAS expression was associated with higher PD-L1 mRNA expression and tumor mutational burden. We speculate that N-RAS transcript level might be a novel biomarker for prognostication and treatment response as an adjunct to TNM stage. Further investigation is warranted.

Racial disparities in incidence-based mortality and survival outcomes in testicular cancer in adolescent and young adults.

Journal of Clinical Oncology Oboseh John Ogedegbe, Olanipekun Lanny Ntukidem, Sakshi Bai et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.650

650 Background: Testicular cancer is the most common malignancy in males aged 15-35, with increasing incidence worldwide. Despite overall high survival rates, significant outcome disparities persist across race, socioeconomic status, and geographic location. Addressing these disparities is crucial to ensure equitable access to early diagnosis, treatment, and supportive care for all patients. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) 17 Research database program was utilized to obtain the annual percentage change (APC) in incidence of testicular cancer from 2000 - 2021 for patients aged 15 - 39 years (AYA group). Patient characteristics were expressed in proportions (%). The Kaplan Meier method was used to determine overall survival (OS) and cancer-specific survival (CSS). Cox regression was performed to determine predictors of survival. A p-value ≤0.05 was considered statistically significant. Results: A total of 19680 met our specified criteria and were included in our studies. We excluded cases with unknown race, and non testicular cancer cases. Our reference race was Hispanics. Compared to Hispanics. Non hispanic American Indian/Alaska Native had HR 1.696, (CI 1.290-2.229, p < 0.001, Non hispanic Asian/Pacific Islander had HR 0.880 (CI 0.712-1.087, p = 0.234), Non Hispanic Blacks had HR 1.608 (CI 1.267-2.039, p < 0.001), Non Hispanic Whites had HR 0.770 (CI 0.682-0.870, p < 0.001). Conclusions: Our study reveals significant racial disparities in testicular cancer survival outcomes with Non hispanic American Indian/Alaska Native and Non Hispanic Blacks having higher mortality risk. These findings highlight the need for targeted interventions to address survival disparities in testicular cancer across different racial and ethnic groups within the AYA demographic.

Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).

Journal of Clinical Oncology Arun Azad, Neeraj Agarwal, Andrew J. Armstrong et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps279

TPS279 Background: PARP inhibitors (PARPi) in combination with androgen receptor pathway inhibitors (ARPIs) are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARPi utilization in earlier lines of treatment may result in greater magnitude of benefit. Saruparib is a potential best-in-class PARPi, which selectively inhibits and traps PARP1, has minimal effect on PARP2, and hence may offer an improved therapeutic window compared with currently approved nonselective PARPi. The efficacy and safety of saruparib plus ARPIs for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and mCRPC are being assessed in the phase I/IIa PETRANHA study (NCT05367440). The phase III EvoPAR-Prostate01 study (NCT06120491) is evaluating the efficacy and safety of saruparib plus physician’s choice of ARPI (abiraterone, darolutamide, or enzalutamide) compared with placebo plus physician’s choice of ARPI in participants with mHSPC. Methods: This is a 2-cohort, 2-arm, randomized, double-blind, placebo-controlled, multicenter global study. Key eligibility criteria include age ≥18 years, histologically confirmed mHSPC ( de novo or recurrent low- or high-volume disease), ECOG PS 0-1, and confirmed, prospectively defined homologous recombination repair gene mutation (HRRm) status (defined by the presence/absence of pathogenic/likely pathogenic mutations in ≥1 of the genes BRCA1 , BRCA2 , ATM , CDK12 , PALB2 , RAD51B , RAD51C , RAD51D , and BARD1 ). Participants must be receiving androgen deprivation therapy throughout the study or have undergone bilateral orchiectomy, and must be suitable for treatment with ARPIs. Key exclusion criteria include prior therapy with PARPi, prior chemotherapy or ARPIs in the mHSPC setting (prior ARPIs for localized disease permitted), and history of, or suspected, myelodysplastic syndrome/acute myeloid leukemia. Participants are allocated to either the HRRm or non-HRRm cohort based on prospective testing of both tumor tissue and circulating tumor DNA. Participants are randomized 1:1 to receive saruparib plus physician’s choice of ARPI or placebo plus physician’s choice of ARPI. Treatment continues until disease progression, unacceptable toxicity, or participant-initiated withdrawal. The primary endpoint is radiographic progression-free survival (rPFS), with overall survival (OS) a key secondary endpoint. Planned statistical analyses of rPFS and OS will be conducted within each cohort using a stratified log-rank test. Approximately 1,800 participants (550 HRRm; 1,250 non-HRRm) will be randomized. Enrollment began in November 2023 and is ongoing. Clinical trial information: NCT06120491 .